Trusted worldwide, nearly 100 million doses administered worldwide，powered by science

Anflu^®：China's first preservative-free split-virion influenza vaccine

Panflu^®：China's first pandemic influenza vaccine (H5N1)

Panflu.1^®：The world's first influenza A (H1N1) vaccine and its mass vaccination was conducted first in the world.

TetrAnflu：Supplemental approval obtained to expand vaccination toindividuals 6 months of age and older, safeguarding the health of abroader population.

Adopted Widely and Globally

SINOVAC's influenza vaccines have been over 100 million doses administered across nearly 20 countries and regions.¹

The influenza vaccine product portfolio is diverse, has gained wide recognition both domestically and internationally, and thereby contributes to the support of global influenza prevention and control efforts.

Superior Quality

Preservative-free formulation，stringent limits for endotoxins, formaldehyde, and ovalbumin that exceed the Chinese Pharmacopoeia (ChP) and the European Pharmacopoeia (Ph. Eur.) ¹

The internal quality control standards are twice as high as those of the ChP and the Ph. Eur.²

Chinese-patented purification process better ensures product purity.⁴

High Effectiveness and Superior Safety^5-8

International multi-center study: The immunogenic response of SINOVAC's Quadrivalent Influenza Virus Split Vaccine (QIV) exceeded that of a licensed, multinational-manufactured comparator QIV.⁵

Chinese Phase III Clinical Study: The seroprotection rates of SINOVAC's QIVreaching as high as 99.4%.⁶

The overall incidence of adverse reactions was 50% lower than the national average^7,8.

Convenience and Efficiency

Unified specifications enhance the efficiency of inventory management.

Flexible deployment improves the efficiency of vaccination services and management, and meets the emergency needs for influenza prevention and control.

Introduction

[NAME OF THE MEDICINAL PRODUCT]

Generic Name: Influenza Vaccine (Split Virion), Inactivated,Quadrivalent

[COMPOSITION AND DESCRIPTION]

This product is derived from the influenza virus recommended by WHO, which is cultured in chicken embryo, followed by harvest, inactivation, purification and disruption. Finally, a slightly opalescent liquid is obtained.

For haemagglutinins of prevalent strains of influenza virus in current year. Excipients include sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate.

[TARGET GROUPS FOR VACCINATION]

The vaccine is approved for use in people aged 6 months and above, especially in vulnerable people and high-risk population for influenza complications, such as infants, children, senior citizens, the weak and people in influenza epidemic areas.

[THERAPEUTIC INDICATION]

This product can induce body to generate immunoreaction against influenza virus and can be used for prevention of infection caused by the influenza virus strain.

[STRENGTH]

Each package contains 0.5 mL liquid. Single dose of 0.5 mL contains 15 μg haemagglutinin per type of influenza virus strain.

[ADMINISTRATION AND DOSAGE]

1. The preferred sites for injection are the anterolateral aspect of the thigh in infants aged 6-12 months or the deltoid muscle in individuals aged 13 months and above.

2.For prophylactic vaccination during or before influenza pandemic period, children aged 6-35 months should receive 2 doses of 0.5 mL with an interval of 4 weeks; individuals aged 3 years and above should receive 1 dose of 0.5 mL. Prior to use, the vaccine should be brought to room temperature and shaken well, then administered by intramuscular injection.

[PACKAGE] Pre-filled syringe or Vial. The package unit is one syringe or Vial.

[STORAGE] Store and transport between +2°C and +8°C, and protect from light.

[SHELF LIFE] 12 months.

[DRUG APPROVAL NO.]

Pre-filled syringe presentation: GuoYaoZhunZi S20200010

For vail: GuoYaoZhunZi S20217013

[MANUFACTURER] Name: SINOVAC BIOTECH CO., LTD.

[ADVERSE REACTIONS][CONTRAINDICATION] [PRECAUTIONS] [DRUG-DRUG INTERACTIONS][MEDICATION FOR PREGNANT AND LACTATING WOMEN] and other detailed information, please refer to the Product Insert.

Reference

[1] SINOVAC's Influenza Vaccines: Global Cumulative Administration Data Summary (2006 – August 2025)

[2] National Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China [M]. Beijing: China Medical Science Press, 2025.

[3] Sinovac Biotech Co.,Ltd.  Product Registration Standard for Quadrivalent Influenza Virus Split Vaccine

[4] Sinovac Biotech Co.,Ltd.，Purification Methods for Influenza Virus Split Vaccine.201310681952.X[P].2016-12-07.

[5] Yang W, González PA, Xin Q, Reyes MRDL, Villalobos RE, Borja-Tabora CFC, Bermal NN, Kalergis AM, Yu D, Wu W, et al. Immunogenicity and Safety of a Quadrivalent Influenza Vaccine in Population Aged 3 Years and Older in Chile and the Philippines: A Phase 3, Non-Inferiority, Double-Blind, Randomized Controlled Clinical Trial. Vaccines. 2024; 12(8):892. https://doi.org/10.3390/vaccines12080892.

[6] Kai Chu, Kangwei Xu, Rong Tang,et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged 3 years. Vaccine. 2020;38 :5940–5946.

[7] Quadrivalent Influenza Virus Split Vaccine, Anflu® Post-Marketing Safety Data Summary Report (2023)

[8] Zhang Lina ,Li Keli ,Li Yan ,et al.Surveillance of adverse events following immunization in China, 2023[J].CHINESE JOURNAL OF VACCINES AND IMMUNIZATION,2025,31(02):121-131.

(For Reference Only by Medical and Pharmaceutical Professionals)